Canaccord raised the firm’s price target on Illumina (ILMN) to $112 from $105 and keeps a Hold rating on the shares. The firm said they reported 3Q25 results that were ahead of its estimates and FactSet consensus. The company shipped more NovaSeq X instruments than 2Q25 which was relatively in line with year-earlier levels. Illumina’s clinical consumables revenue continued to accelerate, increasing to +12% y/y as clinical customers transition to the NovaSeq X.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $100 from $95 at Barclays
- Illumina Reports Steady Q3 2025 Earnings
- Illumina’s Hold Rating: Balancing Growth Potential with Competitive and Financial Challenges
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Illumina reports Q3 adjusted EPS $1.34, consensus $1.17